Abstract
Abstract. In a double‐blind trial with naproxen sodium 32 patients (15 in the naproxen sodium and 17 in the placebo group) completed the study during three consecutive menstrual cycles.There were no significant differences between the two groups in physical characteristics, obstetric/gynecological histories, including the character of dysmenorrhea, and pretreatment pain intensity scores (p = 0.7).The women were prescribed two tablets (550 mg) at the first sign of menstrual pain and one tablet (275 mg) thereafter every six hours as required.When the scores for pain relief were tallied for the three treatment cycles, the naproxen sodium group averaged 13.7 ± 0.65 SE, while the placebo group averaged 8.8 ± 0.95 SE out of a possible maximal relief score of 18. The difference between the two groups was statistically significant at p‐value of 0.0004. Few patients reported side‐effects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
